Sean Bohen - 21 Sep 2022 Form 4/A - Amendment Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
PRESIDENT AND CEO, Director
Signature
/s/ John B. Moriarty, Jr., Attorney-in-Fact
Issuer symbol
OLMA
Transactions as of
21 Sep 2022
Net transactions value
$0
Form type
4/A - Amendment
Filing time
23 Sep 2022, 17:35:48 UTC
Date Of Original Report
22 Sep 2022
Previous filing
03 Feb 2022
Next filing
02 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Purchase +20,000 +37% 74,279 21 Sep 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amendment is being filed solely to correct the transaction code in column 3 of Table I from code "A" to code "P".
F2 The weighted average purchase price for the transaction reported was $3.16, and the range of prices were between $3.15 and $3.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided.
F3 Includes 5 shares acquired under the issuer's Employee Stock Purchase Plan.